8-K Announcements
6Material company update
Jan 16, 2026·SEC
Material company update
Jan 9, 2026·SEC
Material company update
Nov 19, 2025·SEC
Autonomix Medical, Inc. Common Stock(AMIX)Earnings, Financials & Key Ratios
AMIX•NASDAQ
Price updated Jun 19, 2026
AboutAutonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Show more
- Revenue$0
- EBITDA-$17M-49.3%
- Net Income-$17M-46.5%
- EPS (Diluted)-2.32+64.1%
- ROE-238.89%-64.6%
AMIX Key Insights
Autonomix Medical, Inc. Common Stock (AMIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AMIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AMIX Price & Volume
Autonomix Medical, Inc. Common Stock (AMIX) stock price & volume — 10-year historical chart
Loading chart...
AMIX Growth Metrics
Autonomix Medical, Inc. Common Stock (AMIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-46.51%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.3%
Return on Capital
10 Years-297.61%
5 Years-297.61%
3 Years-213.81%
Last Year-243.45%
AMIX Recent Earnings
Autonomix Medical, Inc. Common Stock (AMIX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (50%)
Q3 2026Latest
Jun 4, 2026Metric
Actual
Est
EPS
$0.23+0.0%
$0.23
Rev
—
—
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$0.36+0.0%
$0.36
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.38+8.0%
$1.50
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.07-20.9%
$0.89
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 4, 2026 | $0.23vs $0.23+0.0% | — |
| Q1 2026 | Feb 11, 2026 | $0.36vs $0.36+0.0% | — |
| Q4 2025 | Nov 12, 2025 | $1.38vs $1.50+8.0% | — |
| Q3 2025 | Aug 13, 2025 | $1.07vs $0.89-20.9% | — |
Based on last 12 quarters of dataView full earnings history →
AMIX Peer Comparison
Autonomix Medical, Inc. Common Stock (AMIX) competitors in Neuromodulation and neuro devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare AMIX vs Peers
Autonomix Medical, Inc. Common Stock (AMIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMIX Income Statement
Autonomix Medical, Inc. Common Stock (AMIX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 12K |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -12K▲ 0% |
Gross Margin % | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - |
Operating Expenses | 13.59M | 1.99M | 12.03M | 11.59M | 17.02M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 13.59M | 1.25M | 5.25M | 6.86M | 9.89M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 4.07K | 745K | 2.23M | 4.72M | 7.14M |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 4.56M | 0 | -12K |
Operating Income | -13.59M▲ 0% | -1.99M▲ 85.4% | -12.03M▼ 504.5% | -11.59M▲ 3.7% | -17.03M▼ 47.0% |
Operating Margin % | - | - | - | - | - |
Operating Income Growth % | - | 85.36% | -504.52% | 3.67% | -47% |
EBITDA | 0 | -1.99M | -11.95M | -11.4M | -17.02M |
EBITDA Margin % | - | - | - | - | - |
EBITDA Growth % | - | - | -500.45% | 4.55% | -49.25% |
D&A (Non-Cash Add-back) | 13.59M | 0 | 81K | 183K | 12K |
EBIT | -13.59M | -1.99M | -15.35M | -11.23M | -17.03M |
Net Interest Income | -218.09K | 0 | 48K | 178K | 319K |
Interest Income | 0 | 0 | 127K | 354K | 319K |
Interest Expense | 218.09K | 0 | 79K | 176K | 0 |
Other Income/Expense | 265.56K | 0 | -3.4M | 178K | 319K |
Pretax Income | -13.33M▲ 0% | -1.99M▲ 85.1% | -15.43M▼ 675.2% | -11.41M▲ 26.0% | -16.71M▼ 46.5% |
Pretax Margin % | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
Net Income | -13.33M▲ 0% | -1.99M▲ 85.1% | -15.43M▼ 675.2% | -11.41M▲ 26.0% | -16.71M▼ 46.5% |
Net Margin % | - | - | - | - | - |
Net Income Growth % | - | 85.07% | -675.18% | 26.03% | -46.49% |
Net Income (Continuing) | -13.33M | -1.99M | -15.43M | -11.41M | -16.71M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.71▲ 0% | -0.11▲ 84.5% | -21.09▼ 19072.7% | -6.46▲ 69.4% | -2.32▲ 64.1% |
EPS Growth % | - | 84.51% | -19072.73% | 69.37% | 64.09% |
EPS (Basic) | -0.71 | -0.11 | -21.10 | -6.46 | -2.32 |
Diluted Shares Outstanding | 18.79M | 18.79M | 731.31K | 1.77M | 72.17M |
Basic Shares Outstanding | 18.79M | 18.79M | 731K | 1.77M | 72.17M |
Dividend Payout Ratio | - | - | - | - | - |
AMIX Balance Sheet
Autonomix Medical, Inc. Common Stock (AMIX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
Total Current Assets | 2.05M | 865K | 9.39M | 9.61M | 7.58M |
Cash & Short-Term Investments | 2.04M | 865K | 8.61M | 9.14M | 7M |
Cash Only | 2.04M | 865K | 8.61M | 9.14M | 7M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 8.73K | 0 | 783K | 473K | 577K |
Total Non-Current Assets | 0 | 0 | 16K | 197K | 19K |
Property, Plant & Equipment | 0 | 0 | 16K | 21K | 19K |
Fixed Asset Turnover | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 176K | 0 |
Total Assets | 2.05M▲ 0% | 865K▼ 57.9% | 9.41M▲ 987.5% | 9.81M▲ 4.2% | 7.6M▼ 22.5% |
Asset Turnover | - | - | - | - | - |
Asset Growth % | - | -57.86% | 987.51% | 4.24% | -22.5% |
Total Current Liabilities | 93.24K | 221K | 777K | 1.71M | 1.71M |
Accounts Payable | 91.62K | 173K | 492K | 676K | 700K |
Days Payables Outstanding | - | - | - | - | 21.29K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.62K | 0 | 0 | 0 | 1M |
Current Ratio | 22.02x | 3.91x | 12.09x | 5.63x | 4.45x |
Quick Ratio | 22.02x | 3.91x | 12.09x | 5.63x | 4.45x |
Cash Conversion Cycle | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 1M | 0 | 0 |
Long-Term Debt | 0 | 0 | 1M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 93.24K | 221K | 1.78M | 1.71M | 1.71M |
Total Debt | 0 | 0 | 1M | 0 | 0 |
Net Debt | -2.04M | -865K | -7.61M | -9.14M | -7M |
Debt / Equity | - | - | 0.13x | - | - |
Debt / EBITDA | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - |
Interest Coverage | -62.33x | - | -194.27x | -63.83x | - |
Total Equity | 1.96M▲ 0% | 644K▼ 67.1% | 7.63M▲ 1084.5% | 8.1M▲ 6.2% | 5.89M▼ 27.2% |
Equity Growth % | - | -67.13% | 1084.47% | 6.17% | -27.21% |
Book Value per Share | 0.10 | 0.03 | 10.43 | 4.59 | 0.08 |
Total Shareholders' Equity | 1.96M | 644K | 7.63M | 8.1M | 5.89M |
Common Stock | 12K | 12K | 19K | 2K | 11K |
Retained Earnings | -21.55M | -23.54M | -38.97M | -50.38M | -67.09M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
AMIX Cash Flow Statement
Autonomix Medical, Inc. Common Stock (AMIX) cash flow — operating, investing & free cash flow history
| Metric | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
Cash from Operations | -387.31K | -1.85M | -6.65M | -8.26M | -12.28M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | -378.79% | -258.5% | -24.22% | -48.73% |
Net Income | -13.33M | -1.99M | -15.43M | -11.41M | -16.71M |
Depreciation & Amortization | 0 | 0 | 81K | 183K | 12K |
Stock-Based Compensation | 0 | 0 | 618 | 1.63M | 529K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 12.74M | 0 | 8.62M | 101K | 4M |
Working Capital Changes | 204.41K | 136.08K | 79K | 1.24M | -107K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 87.08K | 80.91K | 320K | 184K | 24K |
Cash from Investing | 0 | 0 | -19K | -14K | -10K |
Capital Expenditures | 0 | 0 | -19K | -14K | -10K |
CapEx % of Revenue | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 2.43M | 675K | 14.41M | 8.8M | 10.16M |
Debt Issued (Net) | 536K | 0 | 2M | 0 | 0 |
Equity Issued (Net) | 1.89M | 675K | 13.71M | 10.03M | 2.61M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -1.3M | -1.23M | 7.55M |
Net Change in Cash | 2.04M▲ 0% | -1.18M▼ 157.7% | 7.74M▲ 756.5% | 528K▼ 93.2% | -2.13M▼ 503.8% |
Free Cash Flow | -387.31K▲ 0% | -1.85M▼ 378.8% | -6.67M▼ 259.5% | -8.27M▼ 24.1% | -12.29M▼ 48.6% |
FCF Margin % | - | - | - | - | - |
FCF Growth % | - | -378.79% | -259.52% | -24.07% | -48.6% |
FCF per Share | -0.02 | -0.10 | -9.12 | -4.68 | -0.17 |
FCF Conversion (FCF/Net Income) | 0.03x | 0.93x | 0.43x | 0.72x | 0.73x |
Interest Paid | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 |
AMIX Key Ratios
Autonomix Medical, Inc. Common Stock (AMIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
Return on Equity (ROE) | -680.21% | -152.87% | -372.97% | -145.1% | -238.89% |
Debt / Equity | - | - | 0.13x | - | - |
Interest Coverage | -62.33x | - | -194.27x | -63.83x | - |
FCF Conversion | 0.03x | 0.93x | 0.43x | 0.72x | 0.73x |
Related:AMIX Dividend History·AMIX Revenue History·AMIX Price History·AMIX P/E History·AMIX Financial Ratios·AMIX Institutional Holders
AMIX SEC Filings & Documents
Autonomix Medical, Inc. Common Stock (AMIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
AMIX Frequently Asked Questions
Autonomix Medical, Inc. Common Stock (AMIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Autonomix Medical, Inc. Common Stock (AMIX) grew revenue by 0.0% over the past year. Growth has been modest.
Autonomix Medical, Inc. Common Stock (AMIX) reported a net loss of $16.7M for fiscal year 2026.
Dividend & Returns
Autonomix Medical, Inc. Common Stock (AMIX) has a return on equity (ROE) of -238.9%. Negative ROE indicates the company is unprofitable.
Autonomix Medical, Inc. Common Stock (AMIX) had negative free cash flow of $11.1M in fiscal year 2026, likely due to heavy capital investments.